Monday, SystImmune, Bristol Myers Squibb Announced Collaboration Agreement For BL-B01D1; Bristol Myers Squibb to Pay An Upfront Of $800M And Up To $500M In Contingent Near-Term Payments. SystImmune Is Eligible To Receive Additional Up To $7.1B
Portfolio Pulse from Benzinga Newsdesk
SystImmune and Bristol Myers Squibb have entered into a collaboration agreement for the development of BL-B01D1. Bristol Myers Squibb will pay SystImmune an $800M upfront fee and up to $500M in near-term contingent payments. Additionally, SystImmune could receive up to $7.1B based on future milestones.
December 12, 2023 | 12:23 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bristol Myers Squibb has committed a significant upfront payment of $800M and up to $500M in near-term payments to SystImmune for collaboration on BL-B01D1, with potential future payments up to $7.1B.
The collaboration with SystImmune could be a significant long-term investment for Bristol Myers Squibb, indicating a strong commitment to expanding its pipeline. However, the short-term impact on the stock may be neutral as the market digests the news and considers the substantial financial commitment against the potential future benefits. The upfront payment and contingent payments are substantial, but the long-term nature of the deal and the uncertainty of the developmental success may temper immediate stock reactions.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80